Report: cancer drug spend rises, metabolic scripts jump

Share this article:

Spending on cancer treatments is rising much faster than for other common pharmaceuticals, a report issued on Monday said.
Spending on cancer and related medications rose by 15 percent in 2004, nearly double the increase in 2003, according to a report from Medco Health Solutions.
Increased use of Novartis' Gleevec and AstraZeneca's Iressa accounted for most of the jump, the report said.
The report also found that Americans with metabolic syndrome account for $4 of every $10 spent on prescription drugs for adults.
Annual prescription costs for people 20 and older with metabolic syndrome averaged $4,116 last year, 4.2 times the average amount spent on drugs for that age group, the Medco
report said.
Adult use of medication for metabolic syndrome -- a condition marked by excess abdominal fat, diabetes, high blood pressure and cholesterol problems -- jumped 36 percent between 2002 and 2004.
Medco reached its findings by examining prescription records from a random sample of 2 million clients.

 

Share this article:

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.